“…[1,2] Thec ongested polycyclicr ing systems of these alkaloids,a long with their promising bioactivities,m ake them highly attractive synthetic targets. [1a,c,d, 3] Since the pioneering syntheses of several daphniphyllum alkaloids by the Heathcock group, [4] impressive total syntheses of various daphniphyllum alkaloids have been reported by the Carreira, [5] Smith, [6] Li, [7] Hanessian, [8] Fukuyama, [9] Zhai, [10] Dixon, [11] and Qiu groups. [12] Owing to the diversified architectures of daphniphyllum alkaloids,ageneral strategy for efficiently accessing these intriguing targets and determining their pharmaceutical potential would be desirable.B ya nalyzing the chemical skeleton of several daphniphyllum alkaloid subfamilies, including yuzurimine-type (for example,calycinine A), daphnilactone B-type (for example,c aldaphnidine C), calyciphylline A-type (for example,h imalensine A), and daphmanidin A-type (for example,d aphmanidin A) alkaloids,a6/7/5 tricyclic ring scaffold was recognized as the common structural feature (Figure 1).…”